efficacy and safety of iguratimod for the treatment of knee osteoarthritis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010628

Enrollment

Unknown

Registered

2017-01-05

Start date

2017-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

Iguratimod group:Iguratimod

Control group: placebo

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria of knee osteoarthritis; 2. aged from 40 to 70 years; 3. can walk without help.

Exclusion criteria

Exclusion criteria: 1. with other connective tissue disease; 2. pregnant and lactating women; 3. people with history of peptic ulcer and previous gastrointestinal bleeding; 4. people with unstable heart disease; 5. Nonsteroidal Antiinflammatory Drugs allergy or allergies.

Design outcomes

Primary

Measure	Time frame
20 minutes walking pain;	—

Secondary

Measure	Time frame
Joint tenderness;WOMAC(Western Ontario and Maemaster Universities);Short Form (36) Health Survey ;	—

Countries

China

Contacts

Public ContactYuan Feng

Department of Clinical Immunology; Xijing Hospital

154568808@qq.com+86 13720635945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026